Does IRadimed Corporation (NASDAQ:IRMD) Have A Particularly Volatile Share Price?

Anyone researching IRadimed Corporation (NASDAQ:IRMD) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market.

Some stocks are more sensitive to general market forces than others. Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). However, Warren Buffett said ‘volatility is far from synonymous with risk’ in his 2014 letter to investors. So, while useful, beta is not the only metric to consider. To use beta as an investor, you must first understand that the overall market has a beta of one. A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

See our latest analysis for IRadimed

What we can learn from IRMD’s beta value

Given that it has a beta of 1.55, we can surmise that the IRadimed share price has been fairly sensitive to market volatility (over the last 5 years). If the past is any guide, we would expect that IRadimed shares will rise quicker than the markets in times of optimism, but fall faster in times of pessimism. Many would argue that beta is useful in position sizing, but fundamental metrics such as revenue and earnings are more important overall. You can see IRadimed’s revenue and earnings in the image below.

NasdaqCM:IRMD Income Statement, September 21st 2019
NasdaqCM:IRMD Income Statement, September 21st 2019

How does IRMD’s size impact its beta?

IRadimed is a rather small company. It has a market capitalisation of US$255m, which means it is probably under the radar of most investors. It has a relatively high beta, suggesting it is fairly actively traded for a company of its size. Because it takes less capital to move the share price of a small company like this, when a stock this size is actively traded it is quite often more sensitive to market volatility than similar large companies.

What this means for you:

Since IRadimed has a reasonably high beta, it’s worth considering why it is so heavily influenced by broader market sentiment. For example, it might be a high growth stock or have a lot of operating leverage in its business model. In order to fully understand whether IRMD is a good investment for you, we also need to consider important company-specific fundamentals such as IRadimed’s financial health and performance track record. I urge you to continue your research by taking a look at the following:

  1. Future Outlook: What are well-informed industry analysts predicting for IRMD’s future growth? Take a look at our free research report of analyst consensus for IRMD’s outlook.
  2. Past Track Record: Has IRMD been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of IRMD’s historicals for more clarity.
  3. Other Interesting Stocks: It’s worth checking to see how IRMD measures up against other companies on valuation. You could start with this free list of prospective options.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.